Reassessment of CD62L as a marker of pre-effector T cells in the tumor draining lymph nodes of head and neck cancer patients

Scott E. Strome, Elizabeth Martin, Dallas Flies, Dianne Khurana, Diva Salomao, Koji Tamada, Andrei Chapoval, Jan L. Kasperbauer, Kerry D. Olsen, Lieping Chen

Research output: Contribution to journalArticle

Abstract

OBJECTIVES: CD62L was evaluated as a determinant of human pre-effector T cells. STUDY DESIGN AND SETTING: Phenotype and cytokine secretion profiles of CD62L cells were determined based on activation status. RESULTS: CD62L Low T cells demonstrated significantly higher secretion of interleukin (IL)-10 and interferon (IFN)-γ than did CD62LHigh T cells. After activation, the majority of cells expressed high levels of the CD62L surface marker. Postactivation levels of IL-10 production remained elevated or unchanged. In a murine B16 melanoma model, freshly isolated CD62LLow tumor draining lymph nodes (TDLN) T cells showed increased secretion of IL-2 and IL-4 but not of IL-10 or IFN-γ. The surface expression of CD62L and cytokine secretion patterns were maintained after activation with concomitant increases in IL-10. CONCLUSION: Our results provide evidence that CD62LLow T cells in TDLNs of progressively growing squamous cell carcinoma of the head and neck differ phenotypically and functionally from those of mouse origin. SIGNIFICANCE: Characterization of this human CD62LLow T cell population provides initial insight regarding novel surface markers in TDLN T cells that might correlate with antitumor reactivity.

Original languageEnglish (US)
Pages (from-to)180-187
Number of pages8
JournalOtolaryngology - Head and Neck Surgery
Volume126
Issue number2
DOIs
StatePublished - Jan 1 2002
Externally publishedYes

Fingerprint

Head and Neck Neoplasms
Lymph Nodes
T-Lymphocytes
Interleukin-10
Neoplasms
Interferons
Cytokines
Experimental Melanomas
Tumor Biomarkers
Interleukin-4
Interleukin-2
Phenotype
Population

ASJC Scopus subject areas

  • Surgery
  • Otorhinolaryngology

Cite this

Reassessment of CD62L as a marker of pre-effector T cells in the tumor draining lymph nodes of head and neck cancer patients. / Strome, Scott E.; Martin, Elizabeth; Flies, Dallas; Khurana, Dianne; Salomao, Diva; Tamada, Koji; Chapoval, Andrei; Kasperbauer, Jan L.; Olsen, Kerry D.; Chen, Lieping.

In: Otolaryngology - Head and Neck Surgery, Vol. 126, No. 2, 01.01.2002, p. 180-187.

Research output: Contribution to journalArticle

Strome, SE, Martin, E, Flies, D, Khurana, D, Salomao, D, Tamada, K, Chapoval, A, Kasperbauer, JL, Olsen, KD & Chen, L 2002, 'Reassessment of CD62L as a marker of pre-effector T cells in the tumor draining lymph nodes of head and neck cancer patients', Otolaryngology - Head and Neck Surgery, vol. 126, no. 2, pp. 180-187. https://doi.org/10.1067/mhn.2002.122263
Strome, Scott E. ; Martin, Elizabeth ; Flies, Dallas ; Khurana, Dianne ; Salomao, Diva ; Tamada, Koji ; Chapoval, Andrei ; Kasperbauer, Jan L. ; Olsen, Kerry D. ; Chen, Lieping. / Reassessment of CD62L as a marker of pre-effector T cells in the tumor draining lymph nodes of head and neck cancer patients. In: Otolaryngology - Head and Neck Surgery. 2002 ; Vol. 126, No. 2. pp. 180-187.
@article{2be18ed5b2ce4e5b9bdc8bf304ca5846,
title = "Reassessment of CD62L as a marker of pre-effector T cells in the tumor draining lymph nodes of head and neck cancer patients",
abstract = "OBJECTIVES: CD62L was evaluated as a determinant of human pre-effector T cells. STUDY DESIGN AND SETTING: Phenotype and cytokine secretion profiles of CD62L cells were determined based on activation status. RESULTS: CD62L Low T cells demonstrated significantly higher secretion of interleukin (IL)-10 and interferon (IFN)-γ than did CD62LHigh T cells. After activation, the majority of cells expressed high levels of the CD62L surface marker. Postactivation levels of IL-10 production remained elevated or unchanged. In a murine B16 melanoma model, freshly isolated CD62LLow tumor draining lymph nodes (TDLN) T cells showed increased secretion of IL-2 and IL-4 but not of IL-10 or IFN-γ. The surface expression of CD62L and cytokine secretion patterns were maintained after activation with concomitant increases in IL-10. CONCLUSION: Our results provide evidence that CD62LLow T cells in TDLNs of progressively growing squamous cell carcinoma of the head and neck differ phenotypically and functionally from those of mouse origin. SIGNIFICANCE: Characterization of this human CD62LLow T cell population provides initial insight regarding novel surface markers in TDLN T cells that might correlate with antitumor reactivity.",
author = "Strome, {Scott E.} and Elizabeth Martin and Dallas Flies and Dianne Khurana and Diva Salomao and Koji Tamada and Andrei Chapoval and Kasperbauer, {Jan L.} and Olsen, {Kerry D.} and Lieping Chen",
year = "2002",
month = "1",
day = "1",
doi = "10.1067/mhn.2002.122263",
language = "English (US)",
volume = "126",
pages = "180--187",
journal = "Otolaryngology - Head and Neck Surgery",
issn = "0194-5998",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Reassessment of CD62L as a marker of pre-effector T cells in the tumor draining lymph nodes of head and neck cancer patients

AU - Strome, Scott E.

AU - Martin, Elizabeth

AU - Flies, Dallas

AU - Khurana, Dianne

AU - Salomao, Diva

AU - Tamada, Koji

AU - Chapoval, Andrei

AU - Kasperbauer, Jan L.

AU - Olsen, Kerry D.

AU - Chen, Lieping

PY - 2002/1/1

Y1 - 2002/1/1

N2 - OBJECTIVES: CD62L was evaluated as a determinant of human pre-effector T cells. STUDY DESIGN AND SETTING: Phenotype and cytokine secretion profiles of CD62L cells were determined based on activation status. RESULTS: CD62L Low T cells demonstrated significantly higher secretion of interleukin (IL)-10 and interferon (IFN)-γ than did CD62LHigh T cells. After activation, the majority of cells expressed high levels of the CD62L surface marker. Postactivation levels of IL-10 production remained elevated or unchanged. In a murine B16 melanoma model, freshly isolated CD62LLow tumor draining lymph nodes (TDLN) T cells showed increased secretion of IL-2 and IL-4 but not of IL-10 or IFN-γ. The surface expression of CD62L and cytokine secretion patterns were maintained after activation with concomitant increases in IL-10. CONCLUSION: Our results provide evidence that CD62LLow T cells in TDLNs of progressively growing squamous cell carcinoma of the head and neck differ phenotypically and functionally from those of mouse origin. SIGNIFICANCE: Characterization of this human CD62LLow T cell population provides initial insight regarding novel surface markers in TDLN T cells that might correlate with antitumor reactivity.

AB - OBJECTIVES: CD62L was evaluated as a determinant of human pre-effector T cells. STUDY DESIGN AND SETTING: Phenotype and cytokine secretion profiles of CD62L cells were determined based on activation status. RESULTS: CD62L Low T cells demonstrated significantly higher secretion of interleukin (IL)-10 and interferon (IFN)-γ than did CD62LHigh T cells. After activation, the majority of cells expressed high levels of the CD62L surface marker. Postactivation levels of IL-10 production remained elevated or unchanged. In a murine B16 melanoma model, freshly isolated CD62LLow tumor draining lymph nodes (TDLN) T cells showed increased secretion of IL-2 and IL-4 but not of IL-10 or IFN-γ. The surface expression of CD62L and cytokine secretion patterns were maintained after activation with concomitant increases in IL-10. CONCLUSION: Our results provide evidence that CD62LLow T cells in TDLNs of progressively growing squamous cell carcinoma of the head and neck differ phenotypically and functionally from those of mouse origin. SIGNIFICANCE: Characterization of this human CD62LLow T cell population provides initial insight regarding novel surface markers in TDLN T cells that might correlate with antitumor reactivity.

UR - http://www.scopus.com/inward/record.url?scp=19044381386&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19044381386&partnerID=8YFLogxK

U2 - 10.1067/mhn.2002.122263

DO - 10.1067/mhn.2002.122263

M3 - Article

VL - 126

SP - 180

EP - 187

JO - Otolaryngology - Head and Neck Surgery

JF - Otolaryngology - Head and Neck Surgery

SN - 0194-5998

IS - 2

ER -